These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8869466)

  • 1. Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.
    Brackmann HH; Oldenburg J; Schwaab R
    Vox Sang; 1996; 70 Suppl 1():30-5. PubMed ID: 8869466
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome.
    Oldenburg J; Schwaab R; Brackmann HH
    Vox Sang; 1999; 77 Suppl 1():49-54. PubMed ID: 10529689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH; Wei QQ
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract]   [Full Text] [Related]  

  • 5. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry.
    Kruse-Jarres R; Gilsenan A; Spears J; Kaye JA
    Haemophilia; 2015 Mar; 21(2):e122-e124. PubMed ID: 25623889
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of factor VIII inhibitors--a general overview.
    White GC; Roberts HR
    Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How we treat a hemophilia A patient with a factor VIII inhibitor.
    Kempton CL; White GC
    Blood; 2009 Jan; 113(1):11-7. PubMed ID: 18820129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of inhibitors in hemophilia A and the induction of immune tolerance.
    Briët E; Peters M
    Adv Exp Med Biol; 2001; 489():89-97. PubMed ID: 11554594
    [No Abstract]   [Full Text] [Related]  

  • 9. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
    Scott DW; Pratt KP
    Front Immunol; 2019; 10():3078. PubMed ID: 32010137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII inhibitors. Potential for prevention of inhibitor formation by immune tolerance.
    Kaplan J; Genyea C; Secord E
    Semin Thromb Hemost; 2000; 26(2):173-8. PubMed ID: 10919410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 12. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

  • 13. Transient inhibitors in the Recombinate PUP study.
    Rothschild C; Gill J; Scharrer I; Bray G
    Thromb Haemost; 2000 Jul; 84(1):145-6. PubMed ID: 10928491
    [No Abstract]   [Full Text] [Related]  

  • 14. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Haematologica; 2000 Oct; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in the treatment of hemophilia.
    Kessler CM
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):184-7. PubMed ID: 18391917
    [No Abstract]   [Full Text] [Related]  

  • 17. Delineating physiological (natural) autoreactivity from pathological autoimmunity.
    Kazatchkine MD
    Vox Sang; 1996; 70 Suppl 1():24-9. PubMed ID: 8869465
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.
    Mannucci PM; Abshire T; Dimichele D; Santagostino E; Blanchette V
    Haemophilia; 2006 Jul; 12(4):429-34. PubMed ID: 16834746
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
    Smith MP; Spence KJ; Waters EL; Beresford-Webb R; Mitchell MJ; Cuttler J; Alhaq A; Brown SA; Savidge GF
    Thromb Haemost; 1999 Jan; 81(1):35-8. PubMed ID: 9974371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.